Bibliografía (cont):

66- Haffner SM. The Metabolic Síndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease. Am J Cardiol 2006; 97: 3-11.

67- Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 2005 Dec; 47(4):201-10.

68- Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005; 22(9):1129-33.

69- Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16(4):421-7.

70-  Lonardo A, Lombardini S, Scaglioni F, Carulli L, Ricchi M, Ganazzi D, Adinolfi LE, Ruggiero G, Carulli N, Loria P. Hepatic steatosis and insulin resistance: Does etiology make a difference? J Hepatol. 2006;44(1):190-6. 

71- Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987-1000 

72- Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005; 17(8):823-6.

73- Hanley AJG, Williams K, Festa A, Wagenknecht LE,. D’Agostino RB,Haffner SM.  Liver Markers and Development of the Metabolic Syndrome.  The Insulin Resistance Atherosclerosis Study.  Diabetes 54:3140-3147.2005
74- Neuschwander-Tetri BA. Nonalcoholic Steatohepatitis and Metabolic Syndrome. Am J Med Sci 2005;330(6):326-35.

75- Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, Vaudo G,

Mannarino E. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension. 2006; 47(5):881-6.

76- Ebinc H, Ebinc FA, Ozkurt ZN, Dogru T, Yilmaz M. Relationship of left ventricular mass to insulin sensitivity and body mass index in healthy individuals. Acta Cardiol. 2006; 61(4):398-405.

77- Zavaroni I, Ardigo D, Zuccarelli A, Pacetti E, Piatti PM, Monti L, Valtuena S,

Massironi P, Rossi PC, Reaven GM. Insulin resistance/compensatory hyperinsulinemia predict carotid intimal medial thickness in patients with essential hypertension. Nutr Metab Cardiovasc Dis. 2006; 16(1):22-7.

78- Sivanandam S, Sinaiko AR, Jacobs DR Jr, Steffen L, Moran A, Steinberger J. Relation of increase in adiposity to increase in left ventricular mass from

childhood to young adulthood. Am J Cardiol. 2006; 98(3):411-5.

79- He FJ, De Wardener HE, Mac Gregor GA. Controversies in stable coronary artery disease. Lancet 2006; 367(9519): 1313-4

80-Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47(6):1093-100.

81- Reaven G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation. 2005 Nov 15; 112(20):3030-2.

82- Soubrier M, Dougados M. Atherosclerosis and rheumatoid arthritis. Rev Med Interne. 2006 Feb; 27(2):125-36

83- Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis. A population based study. Arthritis Rheum 2005; 52: 722-32.

84-Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis. Arthritis Rheum 2005; 52:402 – 11.

85-Ridker PM, Cannon CO, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2005; 352: 20-8.

86-Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin Therapy, LDL cholesterol, C- reactive protein, and coronary disease. N Engl J Med 2005;352: 29-38

87-Mancini GBJ, Dahlöf B, Diez J. Surrogate markers for cardiovascular disease. Functional markers. Circulation 2004; 109(Suppl IV):22-38.

88-Hansson. Inflammation,atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95.

89-Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109(Suppl II):2-10.

90-Sattar N, McInnes IB. Vascular comorbidity  in rheumatoid arthritis: potencial mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92

91-Jensen OK, Rasmussen C, Mollerup F, Christensen PB, Hansen H, Ekelun S, et al. Hyperhomocysteinemia in rheumatoid arthritis: influence of metrotexate treatment and folic acid supplementation. J Rheumatol 2002; 29:1615-8.

92-Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, Stein CM. High frequency of the metabolic syndrome in patients with systemic lupus

erythematosus: Association with disease characteristics and cardiovascular risk

factors. Ann Rheum Dis. 2006; 21(54):456-78

93- Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003; 26(3):575-81.

94- Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112(5):666-73.

95- Hernandez del Rey R, Armario P, Martin-Baranera M, Castellanos P.

Clustering of cardiovascular risk factors and prevalence of metabolic syndrome

in subjects with resistant hypertension. Med Clin (Barc). 2006;127(7):241-5.

97- Ford ES, Abbasi F, Reaven GM. Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose. Atherosclerosis. 2005; 181(1):143-8.

99- Palmieri V, Bella JN. Metabolic syndrome and left ventricular structure and functional abnormalities. Am J Hypertens. 2006; 19(2):206-7.

100- Pei D, Kuo SW, Wu DA, Lin TY, Hseih MC, Lee CH, Hsu WL, Chen SP, Sheu WH, Li JC. The relationships between insulin resistance and components of metabolic syndrome in Taiwanese Asians. Int J Clin Pract. 2005; 59(12):1408-16.

101- Pei D, Kuo SW, Wu DA, Lin TY, Hseih MC, Lee CH, Hsu WL, Chen SP, Sheu WH, Li JC. The relationships between insulin resistance and components of metabolic syndrome in Taiwanese Asians. Int J Clin Pract. 2005; 59(12):1408-16.

102- Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am. 2004; 33(2):333-50.

103- Alvarez Cosmea A, Lopez Fernandez V, Suarez Garcia S, Arias Garcia T, Prieto Diaz MA, Diaz Gonzalez L. Differences in the prevalence of metabolic syndrome according to the ATP-III  and WHO definitions. Med Clin (Barc). 2005; 124(10):368-70.

103- Kim SH, Chunawala L, Linde R, Reaven GM. Comparison of the 1997 and 2003 American Diabetes Association classification of impaired fasting glucose: impact on prevalence of impaired fasting glucose, coronary heart disease risk factors, and coronary heart disease in a community-based medical practice. J Am Coll Cardiol. 2006; 48(2):293-7.

104- Bloomgarden ZT. European Association for the Study of Diabetes (EASD) 2001 Meeting Diabetes Care.2002; 25:1229-1236

105- Kim SH, Reaven GM. The metabolic syndrome: one step forward, two steps back. Diab Vasc Dis Res. 2004; 1(2):68-75.

106- Butnoriene J, Norkus A, Bunevicius R, Lasas L. Evaluation of diagnostic criteria for metabolic syndrome to identify insulin resistance. Medicina (Kaunas). 2006; 42(6):455-63.

107- Harzallah F, Alberti H, Ben Khalifa F. The metabolic syndrome in an Arab population: a first look at the new International Diabetes Federation criteria. Diabet Med. 2006; 23(4):441-4.

108- Scuteri A, Najjar SS, Morrell CH, Lakatta EG; Cardiovascular Health Study. Diabetes Care. 2005; 28(4):882-7.

109- Lu B, Yang Y, Song X, Dong X, Zhang Z, Zhou L, Li Y, Zhao N, Zhu X, Hu R. An evaluation of the International Diabetes Federation definition of metabolic

syndrome in Chinese patients older than 30 years and diagnosed with type 2

diabetes mellitus. Metabolism. 2006;55(8):1088-96.

110- Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK, Mikhailidis DP. Definitions of metabolic syndrome: Where are we now? Curr Vasc Pharmacol. 2006;4(3):185-97.

111- Balkau B, Charles MA, Drivsholm T, Borch-Jonsen K, Wareham N, Yudkin JS, et al; European Group For The Study OF Insulin Resistance (EGIR) Frecuency of the WHO metabolic syndrome in European Cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376.


En la página siguiente: ANEXOS, GRÁFICOS Y TABLAS SOBRE EL SÍNDROME DE INSULINORRESISTENCIA.